They agreed that such results were achieved despite the limitations imposed by the economic, commercial and financial blockade imposed by the United States on Cuba for more than half a century.
At the Center for Genetic Engineering and Biotechnology (CIGB), in western Havana, they learned first-hand about the creation and development of vaccines to fight Covid-19, a disease caused by the SARS-CoV-2 coronavirus.
They acknowledged the efforts that Cuba has made to achieve high levels of immunization, a result that places it at the head of the world in terms of population vaccinated against the pandemic.
Another achievement made by Cuba is the treatment with CIGB’s Heberprot-P, which has reduced the risk of amputation in patients with diabetic foot ulcers by a high percentage in the Cuban population, Dr. Manuel Raices explained.
Heberon® Alfa R, another product, contains recombinant human interferon alfa 2b and is an important biological response modifier, antiviral, antiproliferative and immunomodulatory. It offers an excellent therapeutic response to viral and immunological diseases and neoplasms.
So far, it has demonstrated its antifibrotic, antiangiogenic effects and acts against diseases of the central nervous system.
CIGB’s Nasalferon turned out to be a safe and tolerable drug, it strengthens the immune system and prevents the replication of the SARS-CoV-2 coronavirus, which causes Covid-19, modifying the number of colonies present in the body.
Another triumph of Cuba’s science is the innovative Jusvinza therapy for patients in serious or critical condition due to Covid-19 in whom a state of hyperinflammation is suspected or identified. It is also indicated to treat patients with rheumatoid arthritis.